{"created":"2023-06-19T10:43:23.120884+00:00","id":3612,"links":{},"metadata":{"_buckets":{"deposit":"409d500a-270f-421c-b447-01f0ae4c90c1"},"_deposit":{"created_by":11,"id":"3612","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3612"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003612","sets":["30:59:221"]},"author_link":["7989","7992","7991","7993","538","7990","7994"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-05-22","bibliographicIssueDateType":"Issued"},"bibliographic_titles":[{},{"bibliographic_title":"Diabetes therapy : research, treatment and education of diabetes and related disorders","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"前川, 聡"}],"nameIdentifiers":[{},{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Introduction:\nThe effectiveness of basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in providing glycemic control in patients with type 2 diabetes (T2D) in Japanese routine practice is not well known. This real-world observational study evaluated the probability of achieving glycemic control in Japanese patients with T2D uncontrolled by oral antidiabetic drugs (OADs) who initiated BI or GLP-1 RA therapy. ","subitem_description_type":"Abstract"},{"subitem_description":"Methods:\nPatients with T2D aged ≥ 18 years initiating BI or GLP-1 RA therapy following treatment with OADs were selected from real-world data (RWD) retrieved from a large electronic medical record database in Japan, using data from 01 January 2010 to 30 June 2019. Patients were required to have glycated hemoglobin (HbA1c) ≥ 7% within 90 days prior to the first prescription of BI or GLP-1 RA. The probability of reaching first HbA1c < 7% was assessed over a 24-month period in cohorts of patients who initiated BI (n = 3477) or GLP-1 RA (n = 780) and in subcohorts by number of OADs at baseline (1, 2, or ≥ 3), HbA1c at baseline (≥ 7 to < 8%, ≥ 8 to < 9%, or ≥ 9%), and age (< 65 or ≥ 65 years). ","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nMean (standard deviation) baseline HbA1c was 9.4% (1.8%) and 8.8% (1.4%) in patients initiating BI or GLP-1 RA therapy, respectively. The cumulative probability of achieving glycemic control was 50.1% with BI and 60.3% with GLP-1 RA therapy, respectively, at 12 months, and 60.8% and 66.6%, respectively, at 24 months. Quarterly (3-month intervals) conditional probabilities of achieving glycemic control decreased over time and were < 10% after 12 months. Patients with more OADs or higher HbA1c at baseline had a lower probability of achieving glycemic control. ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion:\nAmong Japanese patients with T2D who initiated BI or GLP-1 RA therapy after treatment with OADs, the probability of reaching first glycemic control diminished over time. Further therapy intensification is warranted in patients who do not achieve glycemic control within 6-12 months with BI or GLP-1 RA, particularly those with high HbA1c or taking multiple OADs. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Nature"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"32445125","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1007/s13300-020-00836-8"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s13300-020-00836-8","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"©The Author(s) 2020"}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1869-6953","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"BAXTER, Mike"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MORIMOTO, Yukiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TAMIWA, Masami"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HATTORI, Masakatsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"PENG, Xuejun Victor"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"LUBWAMA, Robert"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MAEGAWA, Hiroshi"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-06-23"}],"displaytype":"detail","filename":"s13300-020-00836-8.pdf","filesize":[{"value":"1.2 MB"}],"format":"application/pdf","license_note":"This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"s13300-020-00836-8","url":"https://shiga-med.repo.nii.ac.jp/record/3612/files/s13300-020-00836-8.pdf"},"version_id":"12b98d79-dfc9-480b-882a-2b9ae37c4b46"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Basal insulin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"GLP-1 RA","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Real-world evidence","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Type 2 diabetes","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes."}]},"item_type_id":"4","owner":"11","path":["221"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-06-23"},"publish_date":"2020-06-23","publish_status":"0","recid":"3612","relation_version_is_last":true,"title":["A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T12:16:58.411028+00:00"}